Skip to main content

Table 2 Circulating tumor cells and tumor derived extracellular vesicles

From: Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Biomarker Descriptive Median (range)/number of patients (%)
CTC at T0
(n = 104)
Median (range) 0 (0–141)
Patients with CTC 33 (32)
Patients with CTC > 5 10 (10)
CTC at T1
(n = 63)
Median (range) 0 (0–85)
Patients with CTC 17 (27)
Patients with CTC > 5 2 (3)
Change in CTC
(between T0 and T1)
(n = 63)
Median (range) 0 (− 8 − + 39)
Pts with decrease 11 (16)
Pts with increase 11 (17)
Pts with no change 41 (65)
tdEV at T0
(n = 104)
Median (range) 6.5 (0–1753)
Pts with tdEV≥18 27 (26)
tdEV at T1
(n = 63)
Median (range) 5 (0–1975)
Pts with tdEV≥18 11 (17)
Change in tdEV
(between T0 and T1)
(n = 63)
Median (range) -1 (−46 − + 222)
Pts with decrease 33 (52)
Pts with increase 29 (46)
Pts with no change 1 (2)
  1. Circulating tumor cell (CTC) and tumor derived extracellular vesicle (tdEV) count measured by CellSearch in 7.5 mL of blood aided by automated imaging. For automated imaging the Accept program was used, an open source program introduced by Zeune et al. [20,21,22]